日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab

一种新型生物标志物和易于操作的ELISA方法,用于监测接受依库珠单抗治疗的非典型溶血性尿毒综合征患者的补体抑制情况

Riedl, Magdalena; Hofer, Johannes; Giner, Thomas; Rosales, Alejandra; Häffner, Karsten; Simonetti, Giacomo D; Walden, Ulrike; Maier, Tanja; Heininger, Dorothea; Jeller, Verena; Weiss, Günter; van den Heuvel, Lambert; Zimmerhackl, Lothar B; Würzner, Reinhard; Jungraithmayr, Therese C

Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation

NPHS2基因突变筛查可能有助于预测肾移植后FSGS的复发。

Jungraithmayr, Therese C; Hofer, Katrin; Cochat, Pierre; Chernin, Gil; Cortina, Gerard; Fargue, Sonja; Grimm, Paul; Knueppel, Tanja; Kowarsch, Andreas; Neuhaus, Thomas; Pagel, Philipp; Pfeiffer, Karl P; Schäfer, Franz; Schönermarck, Ulf; Seeman, Tomas; Toenshoff, Burkhard; Weber, Stefanie; Winn, Michelle P; Zschocke, Johannes; Zimmerhackl, Lothar B

A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure

一个大家族携带补体C3功能获得性突变,易患非典型溶血性尿毒综合征、镜下血尿、高血压和慢性肾功能衰竭。

Lhotta, Karl; Janecke, Andreas R; Scheiring, Johanna; Petzlberger, Barbara; Giner, Thomas; Fally, Verena; Würzner, Reinhard; Zimmerhackl, Lothar B; Mayer, Gert; Fremeaux-Bacchi, Veronique

Shiga toxin-mediated hemolytic uremic syndrome: time to change the diagnostic paradigm?

志贺毒素介导的溶血性尿毒症综合征:是时候改变诊断模式了吗?

Martina Bielaszewska, Robin Köck, Alexander W Friedrich, Christof von Eiff, Lothar B Zimmerhackl, Helge Karch, Alexander Mellmann